Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    3.00 (2.11%)
Bid:
140.50
Ask:
144.50
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Statement-COVID-19 & Preliminary Statement

23 Mar 2020 17:47

RNS Number : 2844H
Xaar PLC
23 March 2020
 

Xaar plc

 

Trading update and revised date for full year results 

 

Xaar plc ("Xaar" or the "Group"), the leading inkjet printing technology Group, announces a confirmation of previous guidance and a revised date for the presentation of full year results.

 

Full year results

 

Preliminary financial statements for the 12 months ended 31 December 2019 were scheduled to be released 24 March 2020.

 

The FCA has strongly requested all listed companies observe a moratorium on the publication of preliminary financial statements for at least two weeks.

 

In compliance with this request, Xaar will not be releasing preliminary financial statements, but will publish full audited financial statements within four months of the financial year end, subject to any further guidance from the FCA.

 

Trading update

 

Xaar continues to make good progress with its strategy and re-iterates the preliminary guidance for 2019:

 

The Group expects to report revenues for its continuing operations of £49.4 million for the year ended 31 December 2019.

 

Group cash balances (including cash held for investment in Xaar 3D) were £25.3 million at 31 December 2019.

 

COVID19 - Update

 

The health, safety and security of our employees is our upmost priority and appropriate actions have been taken to our operational procedures to mitigate risk.

 

The Group's trading performance in 2020 to date has been in line with expectations. No orders have been cancelled, however we are mindful of the rapidly changing environment in which the business is operating.

 

While the full implications of COVID-19 on the financial performance for the current financial year are difficult to determine at this stage, the Board remains confident in the long-term prospects of the Group.

 

 

Enquiries:

Xaar plc

+44 (0)1223 423 663 

John Mills, Chief Executive Officer

Ian Tichias, Chief Finance Officer

 

 

Tulchan Communications

+44 (0)20 7353 4200

James Macey White

Giles Kernick

Hollie Ralston

 

About XaarXaar is a world leader in the development of digital inkjet technology. Our technology drives the conversion of analogue printing and manufacturing methods to digital inkjet which is more efficient, more economical and more productive than the traditional methods which have been in use for years. We design and manufacture printheads as well as systems for product decoration and industrial 3D Printing which use our inkjet technology. We are the only truly independent inkjet technology company with over 25 years of know how. We offer unrivalled inkjet expertise including technology and printhead design and development and manufacture highly customised product decoration systems and industrial 3D Printing for volume manufacturing. Our unique technologies and products are the leading enabler for innovation and for driving supply chain efficiencies for many industries. Information about Xaar is at www.xaar.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTPPUQCWUPUGMW
Date   Source Headline
2nd Jun 202612:58 pmRNSTotal Voting Rights
28th May 20269:18 amRNSResult of AGM
6th May 20267:00 amRNSDirector/PDMR Shareholding
5th May 202611:36 amRNSHolding(s) in Company
30th Apr 20264:44 pmRNSHolding(s) in Company
16th Apr 20269:00 amRNSPublication of Annual Report and Notice of AGM
1st Apr 20263:43 pmRNSHolding(s) in Company
24th Mar 20267:05 amRNSFinal Results
23rd Mar 20263:33 pmRNS-RInvestor Presentation via Investor Meet Company
2nd Mar 20262:44 pmRNSTotal Voting Rights
14th Jan 20267:00 amRNSTrading Statement
5th Jan 202612:28 pmRNSTotal Voting Rights
5th Dec 20251:15 pmRNSHolding(s) in Company
1st Dec 202512:15 pmRNSTotal Voting Rights
24th Nov 202511:00 amRNSDirector/PDMR Shareholding
3rd Nov 20252:00 pmRNSTotal Voting Rights
21st Oct 20254:15 pmRNSDirector/PDMR Shareholding
13th Oct 20253:20 pmRNSHolding(s) in Company
2nd Oct 202511:10 amRNSDirector/PDMR Shareholding
2nd Oct 20258:50 amRNSDirector/PDMR Shareholding
1st Oct 20255:00 pmRNSDirector/PDMR Shareholding
1st Oct 20253:30 pmRNSTotal Voting Rights
1st Oct 202512:04 pmRNSTRADING UPDATE and NOTICE OF RESULTS
1st Sep 20254:30 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNS2025 INTERIM RESULTS
5th Aug 20257:00 amRNSBoard changes
1st Aug 20253:45 pmRNSTotal Voting Rights
14th Jul 202510:00 amRNSNotice of Interim Results
7th Jul 20253:30 pmRNSBlock listing Interim Review
2nd Jul 20253:30 pmRNSTotal Voting Rights
30th Jun 20252:00 pmRNSDirector/PDMR Shareholding
3rd Jun 202510:00 amRNSTotal Voting Rights
28th May 20253:30 pmRNSResult of AGM
21st May 20251:00 pmRNSHolding(s) in Company
7th May 20253:30 pmRNSNotification of Transactions of Directors & PDMRs
2nd May 202510:30 amRNSTotal Voting Rights
15th Apr 20251:15 pmRNS2024 Annual Report and Notice of AGM
11th Apr 202512:00 pmRNSHolding(s) in Company
1st Apr 20254:15 pmRNSHolding(s) in Company
1st Apr 20253:30 pmRNSTotal Voting Rights
31st Mar 20253:45 pmRNSNotification of Transactions of Directors & PDMRs
31st Mar 20251:10 pmRNSHolding(s) in Company
28th Mar 202511:30 amRNSHolding(s) in Company
27th Mar 202511:00 amRNSHolding(s) in Company
25th Mar 20255:00 pmRNSNotification of Transactions of Directors & PDMRs
25th Mar 20257:00 amRNSFinal Results
5th Mar 202511:30 amRNSTotal Voting Rights
19th Feb 202510:30 amRNSHolding(s) in Company
10th Feb 202511:00 amRNSHolding(s) in Company
5th Feb 20254:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.